Pancreatic cancer genomics: Where can the science take us?

Clinical Genetics

Volumn 88, Issue 3, 2015, Pages 213-219

  Graham, J S ^a,b   Jamieson, N B ^a,c,d   Rulach, R ^b   Grimmond, S M ^a,e   Chang, D K ^a,f,g,h,i   Biankin, Andrew V ^a,f,g,h,i  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c Academic Development Unit   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^h ST VINCENT'S CLINIC   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Genomics; Next generation sequencing; Pancreatic cancer; Stratified medicine; Translational medicine

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

AMPLICON; CANCER GENETICS; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; COPY NUMBER VARIATION; DRUG BIOAVAILABILITY; EXON; GENE STRUCTURE; GENETIC HETEROGENEITY; GENOME; GENOMIC INSTABILITY; GENOMICS; HUMAN; LONG TERM SURVIVAL; MAINTENANCE THERAPY; NEXT GENERATION SEQUENCING; ONCOLOGY; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSPOSON; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE MANAGEMENT; GENETICS; PANCREAS CARCINOMA; PANCREATIC NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; DISEASE PROGRESSION; GENOMICS; HUMANS; PANCREATIC NEOPLASMS; PRECISION MEDICINE; TREATMENT OUTCOME;

EID: 84938991200     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12536     Document Type: Review

References (41)

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014: 74 (11): 2913-2921.
2. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997: 15 (6): 2403-2413.
3. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007: 25 (15): 1960-1966.
4. Cunningham D, Chau I, Stocken DD et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009: 27 (33): 5513-5518.
5. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011: 364 (19): 1817-1825.
6. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013: 369 (18): 1691-1703.
7. Sultana A, Tudur Smith C, Cunningham D et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007: 96 (8): 1183-1190.
8. Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer 2014: 14 (1): 471.
9. Hudson TJ, Anderson W, Artez A et al. International network of cancer genome projects. Nature 2010: 464 (7291): 993-998.
10. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008: 321 (5897): 1801-1806.
11. Campbell PJ, Yachida S, Mudie LJ et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010: 467 (7319): 1109-1113.
12. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010: 467 (7319): 1114-1117.
13. Biankin AV, Waddell N, Kassahn KS et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012: 491 (7424): 399-405.
14. Song S, Nones K, Miller D et al. qpure: a tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS One 2012: 7 (9): e45835.
15. Mann KM, Ward JM, Yew CC et al. Sleeping beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 2012: 109 (16): 5934-5941.
16. Perez-Mancera PA, Rust AG, van der Weyden L et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012: 486 (7402): 266-270.
17. Cheung HW, Cowley GS, Weir BA et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A 2011: 108 (30): 12372-12377.
18. Samuel N, Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2012: 9 (2): 77-87.
19. Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene 2013: 32 (45): 5253-5260.
20. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013: 500 (7463): 415-421.
21. Von Hoff DD, Stephenson JJ Jr, Rosen P et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010: 28 (33): 4877-4883.
22. Farrell JJ, Elsaleh H, Garcia M et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009: 136 (1): 187-195.
23. Neoptolemos J, Greenhalf W, Ghaneh P, Palmer D, Cox T, Garner E. HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials. J Clin Oncol 2013: 31.
24. Sinn M, Sinn B, Stieler J et al. Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative intended resection: Results from the CONKO-001 trial. J Clin Oncol 2014: 32: 5s.
25. Greenhalf W, Ghaneh P, Neoptolemos JP, et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst 2014: 106 (1): djt347.
26. Ormanns S, Heinemann V, Raponi M et al. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. Eur J Cancer 2014: 50 (11): 1891-1899.
27. Tabernero J, Macarulla T. Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J Clin Oncol 2009: 27 (33): 5487-5491.
28. Ciliberto D, Botta C, Correale P et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013: 49 (3): 593-603.
29. Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009: 115 (2): 359-363.
30. Clark-Knowles KV, O'Brien AM, Weberpals JI. BRCA1 as a therapeutic target in sporadic epithelial ovarian cancer. J Oncol 2010: 2010: 891059.
31. Neuzillet C, Tijeras-Raballand A, Cros J, Faivre S, Hammel P, Raymond E. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev 2013: 32 (3-4): 585-602.
32. Infante JR, Matsubayashi H, Sato N et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007: 25 (3): 319-325.
33. Mantoni TS, Schendel RR, Rodel F et al. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther 2008: 7 (11): 1806-1815.
34. Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011: 29 (34): 4548-4554.
35. Hidalgo M, Plaza C, Illei P et al. O-0004SPARC analysis in the phase III MPACT trial of nab-paclitaxel (NAB-P) plus gemcitabine (GEM) vs gem alone for patients with metastatic pancreatic cancer (PC). Ann Oncol 2014: 25 (Suppl 2): ii106.
36. Sinn M, Sinn BV, Striefler JK et al. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol 2014: 25 (5): 1025-1032.
37. da Cunha SG, Dhani N, Tu D et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010: 116 (24): 5599-5607.
38. Propper D, Davidenko I, Bridgewater J et al. Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. Ann Oncol 2014: 25 (7): 1384-1390.
39. Kaplan R, Maughan T, Crook A et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol 2013: 31 (36): 4562-4568.
40. James ND, Sydes MR, Mason MD et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012: 13 (5): 549-558.
41. Bettegowda C, Sausen M, Leary RJ et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014: 6 (224): 224ra24.